BDKRB1 and amyloidosis: B1R antagonist SSR240612 reduced Aβ deposition (Lacoste et al., 2013) in Tg-SwDI mouse model of AD amyloidosis, while another B1R antagonist R-715 treatment increased Aβ40 and fibrillar Aβ deposition in both transgenic mouse models of AD, Tg-SwDI (Passos et al., 2013) and 5 × familial mice (Asraf et al., 2016).